Evidence map›Paper›PMID 36297298›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Combined

Saiful Islam, Theodosia Teo, Malika Kumarasiri, Martin Slater, Jennifer H Martin, Shudong Wang, Richard Head

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Approaches to repurposing reverse transcriptase antivirals in cancer.British journal of clinical pharmacology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Evolution of Antiretroviral Drug Rilpivirine and Approach to Oncology.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Saiful IslamDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Theodosia TeoDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Malika KumarasiriDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Martin SlaterCresset Discovery, New Cambridge House, Litlington, Royston SG8 0SS, UK.
Jennifer H MartinCentre for Human Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, NSW 2305, Australia.
Shudong WangDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.ORCID 0000-0001-6225-5525
Richard HeadDrug Discovery and Development, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
University of South Australia · AUCresset (United Kingdom) · GBUniversity of Newcastle Australia · AU

Funding

UniSA ventures Pty. Ltd. Catalyst Grant
6 · The paper itself

Abstract

The global burden of cancer necessitates rapid and ongoing development of effective cancer therapies. One promising approach in this context is the repurposing of existing non-cancer drugs for cancer indications. A key to this approach is selecting the cellular targets against which to identify novel repurposed drugs for pre-clinical analysis. Protein kinases are highly sought-after anticancer drug targets since dysregulation of kinases is the hallmark of cancer. To identify potential kinase-targeted drug candidates from the existing portfolio of non-cancer therapeutics, we used combined

Indexed as

cancerkinaserepurposingrilpivirinevirtual screening

Identifiers

PMID36297298
PMCPMC9607353
OpenAlexW4297224783

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.